Ocugen Begins Phase 3 Trial for Gene Therapy to Treat Retinitis Pigmentosa
Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that